These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 2995536

  • 1. Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection.
    Chan WL, Lukig ML, Liew FY.
    J Exp Med; 1985 Oct 01; 162(4):1304-18. PubMed ID: 2995536
    [Abstract] [Full Text] [Related]

  • 2. Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.
    Dix RD, Pereira L, Baringer JR.
    Infect Immun; 1981 Oct 01; 34(1):192-9. PubMed ID: 6271681
    [Abstract] [Full Text] [Related]

  • 3. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD.
    Dix RD, Mills J.
    J Med Virol; 1985 Sep 01; 17(1):9-18. PubMed ID: 2995573
    [Abstract] [Full Text] [Related]

  • 4. Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge.
    Roberts PL, Duncan BE, Raybould TJ, Watson DH.
    J Gen Virol; 1985 May 01; 66 ( Pt 5)():1073-85. PubMed ID: 2582080
    [Abstract] [Full Text] [Related]

  • 5. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
    Wang K, Tomaras GD, Jegaskanda S, Moody MA, Liao HX, Goodman KN, Berman PW, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Haynes BF, Cohen JI.
    J Virol; 2017 Oct 01; 91(19):. PubMed ID: 28701403
    [Abstract] [Full Text] [Related]

  • 6. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
    Manickan E, Rouse RJ, Yu Z, Wire WS, Rouse BT.
    J Immunol; 1995 Jul 01; 155(1):259-65. PubMed ID: 7602102
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity.
    Kümel G, Kaerner HC, Levine M, Schröder CH, Glorioso JC.
    J Virol; 1985 Dec 01; 56(3):930-7. PubMed ID: 2415719
    [Abstract] [Full Text] [Related]

  • 9. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT, Marshall JD, Dorwart MR, Heeke DS, Rao E, Tummala P, Yu L, Cohen GH, Eisenberg RJ, Sloan DD.
    J Virol; 2017 May 01; 91(9):. PubMed ID: 28228587
    [Abstract] [Full Text] [Related]

  • 10. Baculovirus-expressed glycoprotein H of herpes simplex virus type 1 (HSV-1) induces neutralizing antibody and delayed type hypersensitivity responses, but does not protect immunized mice against lethal HSV-1 challenge.
    Ghiasi H, Kaiwar R, Nesburn AB, Wechsler SL.
    J Gen Virol; 1992 Mar 01; 73 ( Pt 3)():719-22. PubMed ID: 1312127
    [Abstract] [Full Text] [Related]

  • 11. Passive immunization of mice with monoclonal antibodies to glycoprotein gB of herpes simplex virus.
    Kino Y, Eto T, Ohtomo N, Hayashi Y, Yamamoto M, Mori R.
    Microbiol Immunol; 1985 Mar 01; 29(2):143-9. PubMed ID: 2989659
    [Abstract] [Full Text] [Related]

  • 12. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2.
    Balachandran N, Bacchetti S, Rawls WE.
    Infect Immun; 1982 Sep 01; 37(3):1132-7. PubMed ID: 6290390
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice.
    Ghiasi H, Kaiwar R, Nesburn AB, Slanina S, Wechsler SL.
    J Virol; 1994 Apr 01; 68(4):2118-26. PubMed ID: 8138996
    [Abstract] [Full Text] [Related]

  • 17. Clonal analysis of T-cell responses to herpes simplex virus: isolation, characterization and antiviral properties of an antigen-specific helper T-cell clone.
    Leung KN, Nash AA, Sia DY, Wildy P.
    Immunology; 1984 Dec 01; 53(4):623-33. PubMed ID: 6209206
    [Abstract] [Full Text] [Related]

  • 18. Protective effects of monoclonal antibodies and immunopurified glycoproteins in primary HSV-1 infection.
    Lukic ML, Liew FY, Chan WL.
    Adv Exp Med Biol; 1985 Dec 01; 186():855-61. PubMed ID: 2996318
    [No Abstract] [Full Text] [Related]

  • 19. Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans.
    Cairns TM, Huang ZY, Whitbeck JC, Ponce de Leon M, Lou H, Wald A, Krummenacher C, Eisenberg RJ, Cohen GH.
    J Virol; 2014 Nov 01; 88(21):12612-22. PubMed ID: 25142599
    [Abstract] [Full Text] [Related]

  • 20. Herpes simplex virus type 1-specific immunity induced by peptides corresponding to an antigenic site of glycoprotein B.
    Mester JC, Highlander SL, Osmand AP, Glorioso JC, Rouse BT.
    J Virol; 1990 Nov 01; 64(11):5277-83. PubMed ID: 1698994
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.